NEWS25 March 2025
ANGLE PLC, based at Surrey Research Park, has announced the successful completion of their projects with AstraZeneca; the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay.
These achievements strengthen ANGLE’s position as a front-runner in the development of circulating tumour cell (CTC) technologies for clinical research and drug development.
New Frontiers in Prostate and Multi-Cancer Diagnostics
ANGLE has successfully completed two innovative assay development projects for AstraZeneca:
- A Parsortix-based Androgen Receptor (AR) assay for use in prostate cancer
- A DNA Damage Response (DDR) micronuclei assay to detect treatment-related DNA damage across multiple cancer types
AstraZeneca has approved both assays and is currently using them to test blood samples from patients, demonstrating the real-time, minimally invasive capabilities of ANGLE’s technology. ANGLE will now offer these tools as validated tests through their clinical lab services and support large-scale clinical trials.
The potential of these assays is significant, with the AR therapeutic market projected to reach $9.2 billion by 2033 and the DDR market forecast to grow to $30.3 billion over the next decade.
This development opens new doors for ANGLE to partner with leading pharmaceutical companies on targeted, personalised medicine initiatives and will significantly increase their market value.
ANGLE Chief Executive Officer, Andrew Newland, commented: “Successful completion of the AstraZeneca assay development projects is a key milestone for the Company in progressing our aim for Parsortix-based CTC analysis to be widely adopted for new and existing drugs to identify the right drug for the right patient at the right time.
There is a clear business case for AstraZeneca and other large pharma to expand their markets for existing drugs by identifying patients expressing the target biomarker on CTCs, as biomarker status can change over time and impact response to treatment.”
ANGLE Supports Surrey Research Park’s CancerBusters Initiative
The Park’s unique CancerBusters initiative fosters collaboration between the University of Surrey’s leading human and animal cancer researchers, cancer experts from innovative companies at Surrey Research Park, including ANGLE PLC, and the wider Surrey Innovation District ecosystem.
Managed by the Park’s dedicated Communications and Engagement team, part of the University of Surrey, participants are supported to exchange expertise and knowledge, and access funding and talent opportunities with the goal of driving tangible progress in cancer diagnostics, treatment and care.
Our CancerBusters initiative is just one of the many unique and pioneering ways the University of Surrey supports teams to thrive and businesses to grow at Surrey Research Park.
If you would like to find out more about opportunities for your business at Surrey Research Park, get in touch today.
